News Big step forward for small cap health tech company AGN.c AGNPF who’s up 10% coming off the announcement they were granted a patent in Japan for Treating Chronic Kidney Disease with drug NP-251 or Repirinast.
Repirinast has data showing it reduced fibrosis by 51% and showed an additive benefit to medicine blood pressure drug telmisartan in a mouse model.
A study published earlier this month found that CKD “is affecting as many as 40 per cent of the elderly population in Canada and other developed countries” meaning there’s clearly a huge opportunity in finding a new solution to CKD.
More on the NR in this CEO interview
https://www.youtube.com/watch?v=H04k_Ek6gPI